Nature's Sunshine Announces Strategic Alliance With Fosun Pharma
Nature's Sunshine enters China, the fastest growing direct selling market in the world, with local strategic partner -- Companies will form a joint venture to market and distribute Nature's Sunshine and Synergy products in China through an innovative multi-channel approach -- Fosun Pharma will acquire approximately 15% stake in Nature's Sunshine, underscoring confidence in its global growth opportunities -- Proceeds of Fosun Pharma investment will fund China market entry and $1.50 per share special one-time cash dividend upon transaction closing
LEHI, Utah, June 26, 2014 -- Nature's Sunshine Products, Inc. (NATR), a leading natural health and wellness company engaged in the manufacture and direct selling of nutritional and personal care products, and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196-SH 2196.HK), a leading healthcare company in the People's Republic of China ("China"), announced today the signing of definitive agreements with respect to the formation of a China joint venture to market and distribute Nature's Sunshine and Synergy products in China and an investment by Fosun Pharma of approximately $46.3 million in Nature's Sunshine common stock to be issued pursuant to a private placement transaction.
- Published: 26 June 2014
- Written by Editor